



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 495/04 (2006.01)

C07D 471/04 (2006.01) A61K 31/519 (2006.01)

C07D 487/00 (2006.01) A61K 31/437 (2006.01)

C07D 491/04 (2006.01)

(21) International Application Number:

PCT/US2022/051717

(22) International Filing Date:

02 December 2022 (02.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/285,833 03 December 2021 (03.12.2021) US

63/348,557 03 June 2022 (03.06.2022) US

(71) Applicant: **DECIPHERA PHARMACEUTICALS, LLC** [US/US]; 200 Smith Street, Waltham, Massachusetts 02451 (US).

(72) Inventors: **AHN, Yu Mi**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **AL-ANI, Gada**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **FLYNN, Daniel L.**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **JAVED, Salim**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **KEARNEY, Patrick**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **LE BOURDONNEC, Bertrand**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **STOLTZ, Kristen**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **ZWICKER, Jeffery**; 200 Smith Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **CHOI, Boyeon** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th Fl, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS



Formula I-A

(57) Abstract: Described herein are compounds of Formula I-A that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.